September 29th, Beijing, China

The 2014 Pharmaceutical Strategy Conference (PSA) will be held on Sep. 29 to Oct. 1 in New York, USA. The theme is Pharma’s strategies for success in a value-driven world: Rewarding risk & Innovation. Dr. Jun Bao, Senior Vice President & Chief Business Officer, will attends the conference on behalf of Shenogen. Dr. Bao will be on the panel Emerging Markets: How Geographic Expansion Adds Growth for Biopharma. This panel will take Sun Pharma buying out Ranbaxy as example, to outline which deal models are succeeding and why, and which deals are driving access to R&D innovation. Other panelists are Paul Zhang (Managing Director, Navigant), Steve Yang (EVP&COO, Wuxi App Tec) and Jimmy Zhang (VP of Transaction, J&J). They will explore healthcare reforms, regulatory slowdown, sales models, as well as compare others emerging markets’ growth trends and implications.

About Shenogen

Shenogen Pharma Group is a drug discovery and development company based in Beijing, China, that dedicated the development of first-in-class therapeutics for cancer treatment. We possess robust intellectual property rights around a novel membrane-bound estrogen receptor, ER-alpha 36, which is related to tumor metastasis. Under the motto of “Better Medicine, Better Life” and a seasoned management team, together with our partners, Shenogen has developed an impressive product pipeline. Our pipeline consists of novel small molecule and antibody therapeutics for cancer treatment which includes liver cancer, breast cancer, other solid tumors and leukemia. Our lead molecule, icaritin, is currently in Ph II clinical trial for treatment of advanced hepatocellular carcinoma.